This study assessed the safety, tolerability, and pharmacokinetics of their leading lipidated IL-22 candidate, CK-0045.

Auvelity, under its generic name bupropion and dextromethorphan, has been approved by the FDA for the treatment of major depressive disorder.

The European Medicines Agency has approved Bristol Myers Squibb's application to use Opdivo (nivolumab) and Yervoy (ipilimumab) as initial treatments.

Venlafaxine received FDA approval for the treatment of major depressive disorder on December 28, 1993.

NGM Bio Secures $122 Million in Series A to Launch Primary Sclerosing Cholangitis Trial and Support Phase 2 Hyperemesis Gravidarum Study.

Vutrisiran received FDA approval on June 13, 2022, under the brand name Amvuttra.

Immutep Gets Approval for Phase I Trial of Novel LAG-3 Agonist Antibody Targeting Autoimmune Disorders.

Amoxicillin and vonoprazan, marketed under the brand name Voquezna Dual Pak, is a combination medication approved by the FDA.

Biotheryx Initiates Phase 1 Trial, Administers Initial Dose of BTX-9341, a Novel Dual Action CDK4/6 Degrader, Alone and with Other Treatments.

Mavacamten received its first approval on 28 April 2022 in the USA for the treatment of adults with symptomatic New York Heart Association (NYHA).

Atara Biotherapeutics announced that the FDA has granted priority review for its Tab-cel® application to treat EBV+ PTLD.

Oteseconazole, with the generic name oteseconazole and marketed under the brand name Vivjoa, is an oral capsule formulation primarily used as an azole antifungal medication.